Mutation profiling in cholangiocarcinoma: Prognostic and therapeutic implications

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Churi, Chaitanya R ^a   Shroff, Rachna ^a   Wang, Ying ^a   Rashid, Asif ^a   Kang, HyunSeon C ^a   Weatherly, Jacqueline ^a   Zuo, Mingxin ^a   Zinner, Ralph ^a   Hong, David ^a   Meric Bernstam, Funda ^a   Janku, Filip ^a   Crane, Christopher H ^a   Mishra, Lopa ^a   Vauthey, Jean Nicholas ^a   Wolff, Robert A ^a   Mills, Gordon ^a   Javle, Milind ^a   Creighton, Chad ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FIBROBLAST GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE 1; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN MCL 1; PROTEIN P53; SCATTER FACTOR RECEPTOR; SMAD4 PROTEIN; ONCOPROTEIN;

ADULT; AGED; ARID1A GENE; ARTICLE; BAP1 GENE; BILE DUCT CARCINOMA; BONE METASTASIS; CANCER PROGNOSIS; CANCER SURVIVAL; CDKN2A GENE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DNA REPAIR; ERBB2 GENE; EXON; FBXW7 GENE; FEMALE; FGFR GENE; GENE; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DIFFERENCE; HUMAN; HUMAN TISSUE; IDH1 GENE; INTRON; KRAS GENE; MAJOR CLINICAL STUDY; MALE; MAPK GENE; MCL1 GENE; MIDDLE AGED; MTOR GENE; NEXT GENERATION SEQUENCING; PBRM1 GENE; SMAD4 GENE; TP53 GENE; TREATMENT INDICATION; CHOLANGIOCARCINOMA; DEMOGRAPHY; DISEASE FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; GENETICS; HUMAN GENOME; INTRAHEPATIC BILE DUCT; MOLECULARLY TARGETED THERAPY; MULTIVARIATE ANALYSIS; MUTATION; PATHOLOGY; PROGNOSIS; REGRESSION ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR GENE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DEMOGRAPHY; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, NEOPLASM; GENOME, HUMAN; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTIVARIATE ANALYSIS; MUTATION; ONCOGENE PROTEINS, FUSION; PROGNOSIS; RECEPTORS, FIBROBLAST GROWTH FACTOR; REGRESSION ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84919800397     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115383     Document Type: Article

References (44)

1. Shaib Y, El-Serag HB (2004) The epidemiology of cholangiocarcinoma. Semin Liver Dis 24: 115-125.
2. Shaib YH, Davila JA, McGlynn K, El-Serag HB (2004) Rising incidence of intrahepatic cholangiocarcinoma in the United States: A true increase? J Hepatol 40: 472-477.
3. Khan SA, Emadossadaty S, Ladep NG, Thomas HC, Elliott P, et al. (2012) Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol 56: 848-854.
4. Patel T (2001) Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33: 1353-1357.
5. Shin HR, Oh JK, Lim MK, Shin A, Kong HJ, et al. (2010) Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. J Korean Med Sci 25: 1011-1016.
6. Bertuccio P, Bosetti C, Levi F, Decarli A, Negri E, et al. (2013) A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol 24: 1667-1674.
7. Parsi MA (2013) Obesity and cholangiocarcinoma. World J Gastroenterol 19: 457-462.
8. Tyson GL, El-Serag HB (2011) Risk factors for cholangiocarcinoma. Hepatology 54: 173-184.
9. Yamasaki S (2003) Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg 10: 288-291.
10. (2003) Opisthorchis viverrini and opisthorchiasis: The 21st Century review. Proceedings of the Congress of Opisthorchiasis and Cholangiocarcinoma. May 28-30, 2002. Khon Kaen, Thailand. Acta Trop 88: 169-246.
11. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, et al. (2013) Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 45: 1470-1473.
12. Kanagal-Shamanna R, Portier BP, Singh RR, Routbort MJ, Aldape KD, et al. (2014) Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol 27: 314-327.
13. Ross JS, Cronin M (2011) Whole cancer genome sequencing by next-generation methods. American journal of clinical pathology 136: 527-539.
14. Gnirke A, Melnikov A, Maguire J, Rogov P, LeProust EM, et al. (2009) Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nature biotechnology 27: 182- 189.
15. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, et al. (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31: 3997- 4013.
16. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, et al. (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273-1281.
17. Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, et al. (2011) Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43: 1018-1021.
18. Murali R, Wiesner T, Scolyer RA (2013) Tumours associated with BAP1 mutations. Pathology 45: 116- 126.
19. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, et al. (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330: 1410-1413.
20. van Essen TH, van Pelt SI, Versluis M, Bronkhorst IH, van Duinen SG, et al. (2014) Prognostic parameters in uveal melanoma and their association with BAP1 expression. Br J Ophthalmol.
21. Dawson MA, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150: 12-27.
22. Chen TC, Jan YY, Yeh TS (2012) K-ras mutation is strongly associated with perineural invasion and represents an independent prognostic factor of intrahepatic cholangiocarcinoma after hepatectomy. Ann Surg Oncol 19 Suppl 3: S675-S681.
23. Hamidi H, Lu M, Chau K, Anderson L, Fejzo M, et al. (2014) KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition. Br J Cancer.
24. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351- 1356.
25. Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, et al. (2008) KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Br J Cancer 99: 2020-2028.
26. Javle M, Rashid A, Churi C, Kar S, Zuo M, et al. (2014) Molecular characterization of gallbladder cancer using somatic mutation profiling. Hum Pathol 45: 701-708.
27. Roa I, de Toro G, Schalper K, de Aretxabala X, Churi C, et al. (2014) Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer. Gastrointest Cancer Res 7: 42-48.
28. Lee JW, Soung YH, Kim SY, Nam SW, Park WS, et al. (2006) ERBB2 kinase domain mutation in the lung squamous cell carcinoma. Cancer Lett 237: 89-94.
29. Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12: 175-180.
30. Herter-Sprie GS, Greulich H, Wong KK (2013) Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment. Front Oncol 3: 86.
31. Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, et al. (2008) Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98: 418-425.
32. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, et al. (2013) Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3: 224-237.
33. Bose P, Ozer H (2009) Neratinib: An oral, irreversible dual EGFR/HER2 inhibitor for breast and nonsmall cell lung cancer. Expert Opin Investig Drugs 18: 1735-1751.
34. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, et al. (2013) Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 3: 636-647.
35. Arai T, Nagino M, Nimura Y (2006) [Surgical treatment for hilar cholangiocarcinoma]. Nihon Rinsho 64 Suppl 1: 476-478.
36. Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, et al. (2014) Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet 10: e1004135.
37. Choi W, Porten S, Kim S, Willis D, Plimack ER, et al. (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25: 152-165.
38. Goeppert B, Frauenschuh L, Renner M, Roessler S, Stenzinger A, et al. (2014) BRAF V600Especific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Mod Pathol 27: 1028-1034.
39. Sia D, Tovar V, Moeini A, Llovet JM (2013) Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene 32: 4861-4870.
40. Kipp BR, Voss JS, Kerr SE, Barr Fritcher EG, Graham RP, et al. (2012) Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol 43: 1552-1558.
41. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, et al. (2012) Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 17: 72-79.
42. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, et al. (2013) Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget 4: 156-165.
43. Chung JY, Hong SM, Choi BY, Cho H, Yu E, et al. (2009) The expression of phospho-AKT, phosphomTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res 15: 660-667.
44. Pirozzi CJ, Reitman ZJ, Yan H (2013) Releasing the block: setting differentiation free with mutant IDH inhibitors. Cancer Cell 23: 570-572.